James F. Tessmer

All filings by James F. Tessmer on record concern Lexicon Pharmaceuticals, Inc. Over a trading history stretching from 12 February 2009 to 15 March 2021, the count stands at 63 filings.

In open-market terms, that means 1 purchase worth €10k on one side and 5 sales worth €331k on the other. On balance, insiders were net sellers of €321k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 18 share grants and 39 option exercises. Since January 2021: no purchases and 2 sales on the market.

On 16 March 2021 came the latest disclosure, an open-market sale for €63k in Lexicon Pharmaceuticals, Inc. The most recent open-market purchase was published on 2 August 2019, 2,655 days ago. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.